Cargando…

Addressing multilevel barriers to clinical trial participation among Black and White men with prostate cancer through the PACCT study

BACKGROUND: Cancer clinical trial participation is low and inequitable. Partnering Around Cancer Clinical Trials (PACCT) addressed systemic and interpersonal barriers through an observational study of eligibility and an intervention to improve patient–physician communication and trial invitation rat...

Descripción completa

Detalles Bibliográficos
Autores principales: Eggly, Susan, Senft, Nicole, Kim, Seongho, Heath, Elisabeth I., Jang, Hyejeong, Moore, Tanina F., Baidoun, Fatmeh, Manning, Mark A., Penner, Louis A., Albrecht, Terrance L., Carducci, Michael A., Lansey, Dina, Hamel, Lauren M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134336/
https://www.ncbi.nlm.nih.gov/pubmed/36540051
http://dx.doi.org/10.1002/cam4.5552
_version_ 1785031741124116480
author Eggly, Susan
Senft, Nicole
Kim, Seongho
Heath, Elisabeth I.
Jang, Hyejeong
Moore, Tanina F.
Baidoun, Fatmeh
Manning, Mark A.
Penner, Louis A.
Albrecht, Terrance L.
Carducci, Michael A.
Lansey, Dina
Hamel, Lauren M.
author_facet Eggly, Susan
Senft, Nicole
Kim, Seongho
Heath, Elisabeth I.
Jang, Hyejeong
Moore, Tanina F.
Baidoun, Fatmeh
Manning, Mark A.
Penner, Louis A.
Albrecht, Terrance L.
Carducci, Michael A.
Lansey, Dina
Hamel, Lauren M.
author_sort Eggly, Susan
collection PubMed
description BACKGROUND: Cancer clinical trial participation is low and inequitable. Partnering Around Cancer Clinical Trials (PACCT) addressed systemic and interpersonal barriers through an observational study of eligibility and an intervention to improve patient–physician communication and trial invitation rates. METHODS: Physicians at two comprehensive cancer centers and Black and White men with prostate cancer participated. Patients were followed for 2 years to determine whether they became potentially eligible for an available therapeutic trial. Potentially eligible patients were randomized to receive a trials‐focused Question Prompt List or usual care. Patient–physician interactions were video‐recorded. Outcomes included communication quality and trial invitation rates. Descriptive analyses assessed associations between sociodemographic characteristics and eligibility and effects of the intervention on outcomes. RESULTS: Only 44 (22.1%) of participating patients (n = 199) became potentially eligible for an available clinical trial. Patients with higher incomes were more often eligible (>$80,000 vs. <$40,000, adjusted OR = 6.06 [SD, 1.97]; $40,000–$79,000 vs. <$40,000, adjusted OR = 4.40 [SD, 1.81]). Among eligible patients randomized to the intervention (n = 19) or usual care (n = 25), Black patients randomized to the intervention reported participating more actively than usual care patients, while White intervention patients reported participating less actively (difference, 0.41 vs. −0.34). Intervention patients received more trial invitations than usual care patients (73.7% vs. 60.0%); this effect was greater for Black (80.0% vs. 30.0%) than White patients (80.0% vs. 66.7%). CONCLUSIONS: Findings suggest the greatest enrollment barrier is eligibility for an available trial, but a communication intervention can improve communication quality and trial invitation rates, especially for eligible Black patients.
format Online
Article
Text
id pubmed-10134336
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-101343362023-04-28 Addressing multilevel barriers to clinical trial participation among Black and White men with prostate cancer through the PACCT study Eggly, Susan Senft, Nicole Kim, Seongho Heath, Elisabeth I. Jang, Hyejeong Moore, Tanina F. Baidoun, Fatmeh Manning, Mark A. Penner, Louis A. Albrecht, Terrance L. Carducci, Michael A. Lansey, Dina Hamel, Lauren M. Cancer Med RESEARCH ARTICLES BACKGROUND: Cancer clinical trial participation is low and inequitable. Partnering Around Cancer Clinical Trials (PACCT) addressed systemic and interpersonal barriers through an observational study of eligibility and an intervention to improve patient–physician communication and trial invitation rates. METHODS: Physicians at two comprehensive cancer centers and Black and White men with prostate cancer participated. Patients were followed for 2 years to determine whether they became potentially eligible for an available therapeutic trial. Potentially eligible patients were randomized to receive a trials‐focused Question Prompt List or usual care. Patient–physician interactions were video‐recorded. Outcomes included communication quality and trial invitation rates. Descriptive analyses assessed associations between sociodemographic characteristics and eligibility and effects of the intervention on outcomes. RESULTS: Only 44 (22.1%) of participating patients (n = 199) became potentially eligible for an available clinical trial. Patients with higher incomes were more often eligible (>$80,000 vs. <$40,000, adjusted OR = 6.06 [SD, 1.97]; $40,000–$79,000 vs. <$40,000, adjusted OR = 4.40 [SD, 1.81]). Among eligible patients randomized to the intervention (n = 19) or usual care (n = 25), Black patients randomized to the intervention reported participating more actively than usual care patients, while White intervention patients reported participating less actively (difference, 0.41 vs. −0.34). Intervention patients received more trial invitations than usual care patients (73.7% vs. 60.0%); this effect was greater for Black (80.0% vs. 30.0%) than White patients (80.0% vs. 66.7%). CONCLUSIONS: Findings suggest the greatest enrollment barrier is eligibility for an available trial, but a communication intervention can improve communication quality and trial invitation rates, especially for eligible Black patients. John Wiley and Sons Inc. 2022-12-20 /pmc/articles/PMC10134336/ /pubmed/36540051 http://dx.doi.org/10.1002/cam4.5552 Text en © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle RESEARCH ARTICLES
Eggly, Susan
Senft, Nicole
Kim, Seongho
Heath, Elisabeth I.
Jang, Hyejeong
Moore, Tanina F.
Baidoun, Fatmeh
Manning, Mark A.
Penner, Louis A.
Albrecht, Terrance L.
Carducci, Michael A.
Lansey, Dina
Hamel, Lauren M.
Addressing multilevel barriers to clinical trial participation among Black and White men with prostate cancer through the PACCT study
title Addressing multilevel barriers to clinical trial participation among Black and White men with prostate cancer through the PACCT study
title_full Addressing multilevel barriers to clinical trial participation among Black and White men with prostate cancer through the PACCT study
title_fullStr Addressing multilevel barriers to clinical trial participation among Black and White men with prostate cancer through the PACCT study
title_full_unstemmed Addressing multilevel barriers to clinical trial participation among Black and White men with prostate cancer through the PACCT study
title_short Addressing multilevel barriers to clinical trial participation among Black and White men with prostate cancer through the PACCT study
title_sort addressing multilevel barriers to clinical trial participation among black and white men with prostate cancer through the pacct study
topic RESEARCH ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134336/
https://www.ncbi.nlm.nih.gov/pubmed/36540051
http://dx.doi.org/10.1002/cam4.5552
work_keys_str_mv AT egglysusan addressingmultilevelbarrierstoclinicaltrialparticipationamongblackandwhitemenwithprostatecancerthroughthepacctstudy
AT senftnicole addressingmultilevelbarrierstoclinicaltrialparticipationamongblackandwhitemenwithprostatecancerthroughthepacctstudy
AT kimseongho addressingmultilevelbarrierstoclinicaltrialparticipationamongblackandwhitemenwithprostatecancerthroughthepacctstudy
AT heathelisabethi addressingmultilevelbarrierstoclinicaltrialparticipationamongblackandwhitemenwithprostatecancerthroughthepacctstudy
AT janghyejeong addressingmultilevelbarrierstoclinicaltrialparticipationamongblackandwhitemenwithprostatecancerthroughthepacctstudy
AT mooretaninaf addressingmultilevelbarrierstoclinicaltrialparticipationamongblackandwhitemenwithprostatecancerthroughthepacctstudy
AT baidounfatmeh addressingmultilevelbarrierstoclinicaltrialparticipationamongblackandwhitemenwithprostatecancerthroughthepacctstudy
AT manningmarka addressingmultilevelbarrierstoclinicaltrialparticipationamongblackandwhitemenwithprostatecancerthroughthepacctstudy
AT pennerlouisa addressingmultilevelbarrierstoclinicaltrialparticipationamongblackandwhitemenwithprostatecancerthroughthepacctstudy
AT albrechtterrancel addressingmultilevelbarrierstoclinicaltrialparticipationamongblackandwhitemenwithprostatecancerthroughthepacctstudy
AT carduccimichaela addressingmultilevelbarrierstoclinicaltrialparticipationamongblackandwhitemenwithprostatecancerthroughthepacctstudy
AT lanseydina addressingmultilevelbarrierstoclinicaltrialparticipationamongblackandwhitemenwithprostatecancerthroughthepacctstudy
AT hamellaurenm addressingmultilevelbarrierstoclinicaltrialparticipationamongblackandwhitemenwithprostatecancerthroughthepacctstudy